724
Participants
Start Date
April 30, 2012
Primary Completion Date
October 10, 2017
Study Completion Date
May 31, 2018
Axitinib
Axitinib 5 mg twice daily
Placebo
Placebo twice daily
New York
Albany
Washington D.C.
Annapolis
Norfolk
Charleston
Atlanta
Ocala
Chattanooga
Saint Paul
Omaha
Dallas
Bedford
Houston
San Antonio
San Antonio
Austin
Denver
Los Angeles
La Jolla
Palo Alto
Pleasant Hill
Seattle
Portland
Baltimore
Hackensack
Beijing
Changchun
Chongqing
Dalian
Guangzhou
Hangzhou
Jinan
Nanchang
Shanghai
Suzhou
Tianjin
Wuhan
Besançon
Bordeaux
Hyères
Le Mans
Lyon
Marseille
Paris
Rennes
Saint-Herblain
Suresnes
Vandœuvre-lès-Nancy
Hong Kong
Ahmeadbad
Aurangabad
Bangalore
Chennai
Hyderabad
Karamsad
Kochi
Kolkota
Lucknow
Ludhiana
Mangalore
Manipal
Mumbai
Nashik
New Delhi
Pune
Surat
Visakhapatnam
Aichi
Akita
Aomori
Chiba
Fukuoka
Gifu
Hokkaido
Hyōgo
Kagawa
Kanagawa
Kumamoto
Kyoto
Nagasaki
Nigata-honmachi
Osaka
Shizuoka
Tokushima
Tokyo
Yamagata
Yamaguchi
Busan
Daegu
Daejeon
Gyeonggi-do
Jeonnam
Seoul
Barcelona
Donostia / San Sebastian
Leganés
Llobregat
Madrid
Oviedo
Seville
Valencia
Zaragoza
Taichung
Taipei
Taoyuan District
Collaborators (1)
Pfizer
INDUSTRY
SFJ Pharmaceuticals, Inc.
INDUSTRY
SFJ Pharma Ltd. II
INDUSTRY